In the study by van Tintelen et al. 33, the presence of a PKP2 mutation was not associated with higher risks of endpoint events (documented sustained ventricular tachycardia episodes, ventricular fibrillation, appropriate ICD therapy, successful resuscitation and SCD). This evidence concerns the gene PKP2 and ventricular fibrillation.